Nelson Nicolasora, MD
Infectious Disease · Toledo, OHNPI 1407974959
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,600 of the $64,901 with a category attached, or 82.6%. Aimmune Therapeutics, Inc. accounts for 95.0% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $51,883, more than ten times the $636 reported in 2019. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $303.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$62K
- AbbVie$970
- Merck$589
- Paratek Pharmaceuticals, Inc.$386
- Viiv Healthcare Company$344
- Gilead$210
- plus $753 from 10 others
What the payments were for
- Speaking & faculty fees$53,60083%
- Travel & lodging$6,87011%
- Food & beverage$4,2707%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 45 | $61,649 |
| AbbVie(2 entities) | 49 | $970 |
| Merck | 29 | $589 |
| Paratek Pharmaceuticals, Inc. | 22 | $386 |
| Viiv Healthcare Company | 23 | $344 |
| Gilead | 12 | $210 |
| Melinta Therapeutics, LLC | 4 | $173 |
| Insmed, Inc. | 6 | $118 |
| Astellas Pharma US Inc | 3 | $100 |
| Mayne Pharma Commercial LLC | 6 | $98 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $82 |
| Johnson & Johnson | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Pfizer | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $19 |
| Shionogi Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,901 in reported general payments places this provider in the 95th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 44 | $183,511 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 19 | $72,751 |
| CresembaIsavuconazonium Sulfate | 11 | $70,721 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $47,931 |
| TivicayDolutegravir Sodium | 22 | $46,836 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $44,071 |
| JulucaDolutegravir/Rilpivirine | 12 | $41,470 |
| PrezcobixDarunavir/Cobicistat | 15 | $40,779 |
| Daptomycin | 14 | $20,611 |
| ErtapenemErtapenem Sodium | 44 | $15,249 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 22 | $6,908 |
| Vancomycin Hcl | 31 | $4,135 |
| Cefazolin Sodium | 57 | $2,966 |
| Voriconazole | 13 | $2,783 |
| CeftriaxoneCeftriaxone Sodium | 53 | $2,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $210 | $231,44267 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Juluca | $344 | $132,37846 claims |
| Astellas Pharma US IncCresemba | $100 | $70,72111 claims |
| Johnson & JohnsonPrezcobix | $61 | $40,77915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 infectious disease providers in Ohio.
Other infectious disease in Toledo
- Tanyanyiwa ChinyadzaToledo$4K
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
- Thomas FileAkron$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.